Overview
This foundational study examined the toxicity and metabolic fate of palladium and platinum compounds (primarily PdCl2) in rats using multiple exposure routes. The key finding is that oral administration results in almost complete fecal excretion with minimal absorption, while intravenous administration distributes Pd to kidney, spleen, and liver. The study also documents fetal transfer via the IV route in pregnant rats.
Key numbers
- After single oral dose: almost all 103Pd excreted in feces (non-absorption documented)
- After IV dose: Pd distributed to kidney, spleen, liver (highest tissue retention route)
- After IV in pregnant rats: small but measurable 103Pd found in fetuses
- LD50 by multiple routes characterized (specific values in paper)
- Inhalation and intratracheal routes also tested
Methods (brief)
Radiolabeled 103Pd used to track distribution after oral, IV, inhalation, and intratracheal exposure in rats. Tissue distribution measured at defined timepoints post-dosing. Pregnant rat subgroup used to assess placental transfer.
Implications
This page makes the source discoverable for palladium evidence routing. Establishes the foundational basis for the widely cited conclusion that oral palladium has very low bioavailability, with the vast majority excreted in feces rather than absorbed. This low oral bioavailability is the primary pharmacokinetic rationale for limited dietary exposure concern from food-borne Pd.
Related evidence
Update history
No substantive edit history is available in this build. The full commit record is available in git.